ArticleJournal of inflammation research2025
Differential Mediating Roles of Immune-Inflammatory Cells in ≥HSIL Women: A Focus on HPV and CD4/CD8 or NLR.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Macrophage polarization in gynecologic malignancies: key signaling pathways and clinical perspectives.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to investigate the relationship between inflammatory-immune cells and ≥high-grade squamous intraepithelial lesions (HSIL), and to clarify the role of immune-inflammatory cells mediating human papilloma virus (HPV) and ≥HSIL. Methods: We retrospectively enrolled 427 patients with ≥HSIL and 357 ≤low-grade squamous intraepithelial lesions (LSIL) from June 1, 2013 to June 1, 2023. Clinical data such as age, peripheral blood inflammatory-immune cells, serum tumor markers, HPV infection status were collected to evaluate the relationship between clinical indicators and ≥HSIL mediated by inflammatory-immune cells. Results: Compared with the ≤LSIL cohort, the patients with ≥HSIL exhibited a significantly higher prevalence of infection with ≥2 type HPV genotypes compared to those with a single HPV infection (34.55% vs 17.65%, p = 0.045). Multiple HPV infection and lower CD4/CD8 ratio were the independent risk factors for the patients with ≥HSIL besides HPV infection. Moreover, the top three HPV genotypes were HPV-16, HPV-18 and HPV-52 among the populations of ≥HSIL. Interestingly, HPV (1.29%), HPV-16 (2.48%) and HPV-52 (9.70%) infection were partially mediated by CD4/CD8 ratio to promote ≥HSIL (p < 0.05). Furthermore, compared with the HSIL cohort, SCC, HPV16, HPV52 infection and higher neutrophil and lymphocyte ratio (NLR) were the independent risk factors for cervical cancer (CC). Among women with CC, the top three HPV types are 16, 18, and 52. The relationship between HPV/HPV-16 and CC was partially mediated by the NLR, with mediation effect ratios of 1.87% and 2.85%, respectively (p < 0.05). Conclusion: HPV-induced HSIL and CC are associated with immune-inflammatory status. Specifically, the CD4/CD8 ratio plays a significant mediating role during the HSIL stage, whereas NLR assumes a major mediating role in the CC stage. Thus, immune-inflammatory cells play distinct roles at different stages of CC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.